Pharmacology of Penicillin G

1. Introduction/Overview

Penicillin G, also known as benzylpenicillin, represents the prototypical and first widely available antibiotic from the beta-lactam class. Its discovery by Alexander Fleming in 1928 and subsequent development for clinical use marked a pivotal transformation in modern medicine, enabling the effective treatment of previously fatal bacterial infections. As a natural penicillin derived from the fungus Penicillium notatum, it retains significant clinical utility despite the proliferation of numerous semisynthetic derivatives. Its pharmacology serves as the fundamental model for understanding the entire beta-lactam antibiotic family.

The clinical relevance of Penicillin G remains substantial, particularly for infections caused by susceptible Gram-positive organisms, certain Gram-negative cocci, and spirochetes. It continues to be a first-line agent for conditions such as syphilis, streptococcal pharyngitis, and serious infections like meningitis and endocarditis when caused by penicillin-susceptible strains. An understanding of its pharmacology is essential for medical and pharmacy students, as it provides the cornerstone for rational antibiotic prescribing, including concepts of bacterial resistance, antimicrobial spectrum, and the management of hypersensitivity reactions.

Learning Objectives

Upon completion of this chapter, the reader should be able to:

• Describe the chemical structure of Penicillin G and its relationship to the beta-lactam antibiotic class.
• Explain the molecular mechanism of action, including binding to penicillin-binding proteins and inhibition of bacterial cell wall synthesis.
• Analyze the pharmacokinetic profile of Penicillin G, including its absorption, distribution, metabolism, and excretion, and how these properties influence dosing regimens.
• Identify the primary clinical indications for Penicillin G and distinguish them from indications for broader-spectrum penicillins.
• Recognize the spectrum of adverse effects associated with Penicillin G, with particular emphasis on hypersensitivity reactions and neurotoxicity, and outline appropriate management strategies.

2. Classification

Penicillin G is systematically classified within several overlapping hierarchies based on its origin, chemical structure, and antimicrobial spectrum.

Chemical and Pharmacologic Classification

Chemically, Penicillin G is designated as benzylpenicillin. Its core structure consists of a thiazolidine ring fused to a beta-lactam ring, which is essential for antibacterial activity. The side chain attached to the beta-lactam ring is a benzyl group (C₆H₅CH₂-), which confers its specific antibacterial spectrum and susceptibility to bacterial beta-lactamases.

Pharmacologically, it is categorized as follows:

• Antibiotic Class: Beta-lactam antibiotic.
• Penicillin Subclass: Natural penicillin. It is one of the penicillins produced directly by microbial fermentation, as opposed to semisynthetic penicillins which are chemically modified.
• Spectrum Classification: Narrow-spectrum penicillin. Its activity is predominantly against Gram-positive bacteria, some Gram-negative cocci, and anaerobic organisms. It is not effective against most Gram-negative bacilli due to poor penetration of their outer membrane.

It is commercially available in several salt forms, which significantly alter its pharmacokinetic properties:

• Penicillin G Potassium: The most common intravenous and intramuscular formulation. Highly water-soluble.
• Penicillin G Sodium: An alternative parenteral salt, often used when sodium load is preferable to potassium load.
• Penicillin G Procaine: A repository formulation created by combining penicillin G with the local anesthetic procaine. This complex has low solubility, resulting in slow absorption from an intramuscular injection site, providing sustained lower serum concentrations for 12-24 hours.
• Penicillin G Benzathine: The most slowly absorbed repository form. It provides very low but detectable serum concentrations for up to 4 weeks following a single intramuscular dose, making it ideal for prophylaxis and treatment of syphilis and rheumatic fever.

3. Mechanism of Action

The antibacterial activity of Penicillin G is exclusively bactericidal and is exerted through a highly specific inhibition of bacterial cell wall synthesis. This mechanism is contingent upon the structural integrity of the beta-lactam ring.

Molecular and Cellular Mechanisms

The primary biochemical target of Penicillin G is a group of bacterial membrane-bound enzymes known as penicillin-binding proteins (PBPs). PBPs are transpeptidases, carboxypeptidases, and endopeptidases that catalyze the final cross-linking steps in the synthesis of peptidoglycan, the essential mesh-like polymer that provides structural integrity to the bacterial cell wall. Peptidoglycan synthesis involves the polymerization of glycan chains (composed of N-acetylglucosamine and N-acetylmuramic acid) that are cross-linked by peptide side chains.

Penicillin G, due to its structural similarity to the D-alanyl-D-alanine terminus of the peptidoglycan peptide side chain, acts as a substrate analog. It binds covalently and irreversibly to the active serine site of the PBPs, particularly the transpeptidases responsible for forming the cross-links between adjacent glycan strands. This acylation reaction permanently inactivates the enzyme. The beta-lactam ring is cleaved during this process, forming a stable penicilloyl-enzyme complex.

The inhibition of PBP function leads to several downstream consequences:

1. Inhibition of Cross-Link Formation: Without functional transpeptidases, the peptide cross-links between peptidoglycan strands fail to form.
2. Accumulation of Park Nucleotides: UDP-N-acetylmuramyl-pentapeptide precursors accumulate intracellularly.
3. Activation of Autolysins: In many bacteria, cell wall damage triggers the activation or deregulation of endogenous bacterial hydrolases (autolysins), which degrade existing peptidoglycan.

The net result is a weakened, structurally deficient cell wall that cannot withstand the high internal osmotic pressure of the bacterium. This leads to cell lysis and death. The bactericidal effect is most pronounced against rapidly dividing bacteria that are actively synthesizing peptidoglycan.

Spectrum of Activity and Resistance

The antimicrobial spectrum of Penicillin G is intrinsically narrow. Its activity is superb against many Gram-positive cocci and bacilli, including:

• Streptococcus pyogenes (Group A Streptococcus)
• Streptococcus pneumoniae (penicillin-susceptible strains)
• Streptococcus agalactiae (Group B Streptococcus)
• Viridans group streptococci
• Most Enterococcus faecalis (often requiring synergy with an aminoglycoside for bactericidal activity)
• Bacillus anthracis
• Listeria monocytogenes
• Most anaerobes, including Clostridium species (except C. difficile) and non-beta-lactamase producing Bacteroides.

Among Gram-negative organisms, its activity is limited primarily to Neisseria meningitidis and Neisseria gonorrhoeae (though resistance is now widespread in the latter). It is also highly active against spirochetes, notably Treponema pallidum (syphilis).

Bacterial resistance to Penicillin G arises through three principal mechanisms:

1. Beta-Lactamase Production: This is the most common mechanism. Beta-lactamase enzymes hydrolyze the amide bond in the beta-lactam ring, rendering the antibiotic inactive. Penicillin G is highly susceptible to hydrolysis by staphylococcal penicillinase and many broad-spectrum beta-lactamases produced by Gram-negative bacteria.
2. Altered Penicillin-Binding Proteins (PBPs): Bacteria may acquire or mutate PBPs such that they have a markedly reduced affinity for penicillin. This is the mechanism of resistance in methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and enterococci.
3. Impermeability: The outer membrane of Gram-negative bacteria acts as a permeability barrier, preventing Penicillin G from reaching its PBPs in the periplasmic space. Porin channel changes can further reduce uptake.

4. Pharmacokinetics

The pharmacokinetic profile of Penicillin G is characterized by rapid elimination, poor oral bioavailability, and significant variation based on the administered salt form. These properties directly dictate its clinical use as a predominantly parenteral agent.

Absorption

Penicillin G is highly unstable in the acidic environment of the stomach, leading to extensive degradation. Furthermore, its absorption from the gastrointestinal tract is incomplete and erratic. Therefore, oral administration is not recommended for systemic treatment, and it is not commercially available in an oral formulation for adults. For systemic effect, parenteral administration (intravenous or intramuscular) is required.

The rate and extent of absorption from intramuscular sites depend critically on the salt form:

• Potassium or Sodium Salts: Rapidly and completely absorbed, achieving peak serum concentrations (C_max) within 15-30 minutes. The serum concentration profile is characterized by high peaks and rapid decline.
• Procaine Penicillin G: Forms a depot at the injection site. Absorption is slow and sustained, with C_max reached in about 1-4 hours and therapeutic concentrations maintained for 12-24 hours.
• Benzathine Penicillin G: Provides the most prolonged release. Serum concentrations are very low but detectable for up to 4 weeks, which is sufficient to treat syphilis and prevent rheumatic fever recurrence but inadequate for treating acute, severe infections.

Distribution

Penicillin G distributes widely into various body tissues and fluids. Its volume of distribution is approximately 0.3 to 0.4 L/kg, indicating distribution primarily into extracellular fluid. It achieves adequate concentrations in kidneys, liver, skin, and intestines. Penetration into certain sites is more limited:

• Central Nervous System (CNS): Penetration across the uninflamed blood-brain barrier is poor. However, during active meningitis, inflammation increases capillary permeability, allowing therapeutic concentrations to be achieved in the cerebrospinal fluid (CSF), especially with high-dose intravenous regimens (e.g., 18-24 million units daily). CSF concentrations may reach 5-10% of simultaneous serum levels.
• Prostate, Bone, and Ocular Humor: Penetration is generally low.
• Placenta and Breast Milk: Penicillin G crosses the placenta and is excreted in breast milk in low concentrations.

Protein binding is moderate, ranging from 45% to 65%, primarily to albumin. Only the unbound fraction is pharmacologically active.

Metabolism

A significant portion of Penicillin G is metabolized. The primary pathway involves hydrolysis of the beta-lactam ring to inactive penicilloic acid, which occurs spontaneously to some degree in aqueous solution and is accelerated by bacterial beta-lactamases in vivo. Hepatic metabolism is not a major route of elimination. The penicilloic acid metabolite can act as a hapten and is implicated in some hypersensitivity reactions.

Excretion

Renal excretion is the dominant route of elimination for Penicillin G. The process is rapid and efficient, involving two mechanisms:

1. Glomerular Filtration: Approximately 10-20% of the drug is excreted unchanged by this passive process.
2. Active Tubular Secretion: The majority (about 80%) is actively secreted into the urine via the organic anion transporter system in the proximal renal tubules. This saturable transport system is responsible for the drug’s very short elimination half-life.

The elimination half-life (t_1/2) of intravenous Penicillin G potassium or sodium is exceptionally short, typically ranging from 30 to 60 minutes in adults with normal renal function. This necessitates frequent dosing or continuous intravenous infusion to maintain serum concentrations above the minimum inhibitory concentration (MIC) for susceptible pathogens. The half-life is markedly prolonged in renal impairment and in neonates due to immature renal function.

The relationship between dose, clearance, and area under the curve (AUC) can be described by the equation: AUC = Dose ÷ Clearance. Since renal clearance is the primary determinant of total clearance, any reduction in renal function necessitates dose adjustment to prevent accumulation and toxicity.

5. Therapeutic Uses/Clinical Applications

Despite its age, Penicillin G retains specific, vital roles in antimicrobial therapy, primarily for infections caused by highly susceptible organisms. Its use is guided by microbiological susceptibility testing whenever possible.

Approved Indications

The primary clinical applications of Penicillin G include:

• Streptococcal Infections:
  • Group A Streptococcus (S. pyogenes): First-line for pharyngitis, scarlet fever, erysipelas, cellulitis, and necrotizing fasciitis. It is also the drug of choice for prophylaxis of rheumatic fever and acute glomerulonephritis.
  • Streptococcus pneumoniae: For penicillin-susceptible strains causing pneumonia, meningitis, otitis media, and bacteremia.
  • Viridans Streptococci: A key component of therapy for infective endocarditis, often combined with an aminoglycoside for synergy.
• Syphilis: Penicillin G remains the undisputed first-line therapy for all stages of syphilis caused by Treponema pallidum. The formulation depends on the stage:
  • Early (primary, secondary, early latent): Benzathine penicillin G, single intramuscular dose.
  • Late latent, tertiary, or neurosyphilis: Requires longer courses, often with higher-dose intravenous penicillin G for neurosyphilis.
• Meningococcal Infections: High-dose intravenous Penicillin G is an effective treatment for meningitis and meningococcemia caused by susceptible Neisseria meningitidis, though third-generation cephalosporins are often preferred empirically.
• Clostridial Infections: High-dose intravenous therapy is used for gas gangrene (Clostridium perfringens) and tetanus (C. tetani), alongside surgical debridement and antitoxin.
• Other Specific Infections: Includes actinomycosis, rat-bite fever (Streptobacillus moniliformis), and infections caused by Listeria monocytogenes, Pasteurella multocida, and Bacillus anthracis (anthrax).

Off-Label Uses

Common off-label applications are generally extensions of its spectrum based on historical efficacy and guidelines, though susceptibility confirmation is critical. These may include treatment of certain Enterococcus faecalis infections (with an aminoglycoside) and as part of combination regimens for severe odontogenic infections. Its use for gonorrhea is now obsolete due to near-universal resistance.

6. Adverse Effects

Penicillin G is generally well-tolerated from a non-allergic perspective, but it carries a significant risk of hypersensitivity reactions. Adverse effects can be categorized as allergic, toxic, or related to electrolyte disturbances from the salt formulation.

Common Side Effects

• Hypersensitivity Reactions: These are the most frequent adverse events, occurring in approximately 1-10% of patients. Manifestations range from mild to life-threatening.
  • Maculopapular Rash: A common, delayed (onset after several days), non-IgE-mediated rash.
  • Drug Fever: A febrile reaction that resolves upon discontinuation.
  • Serum Sickness-Like Reaction: Characterized by fever, arthralgias, and urticaria, typically occurring 1-3 weeks after initiation.
• Local Reactions: Pain and inflammation at intramuscular injection sites, particularly with procaine and benzathine formulations. Intravenous administration can cause phlebitis.
• Gastrointestinal Disturbances: Nausea, vomiting, and diarrhea may occur, though less commonly than with broad-spectrum antibiotics, as Penicillin G has minimal effect on gut anaerobes.

Serious/Rare Adverse Reactions

• Anaphylaxis: An acute, IgE-mediated, life-threatening reaction characterized by bronchospasm, laryngeal edema, hypotension, and cardiovascular collapse. The estimated incidence is 0.004-0.04%. It is an absolute contraindication to future penicillin administration.
• Interstitial Nephritis: An immune-mediated renal injury presenting with fever, rash, eosinophilia, eosinophiluria, and acute kidney injury. It is usually reversible upon drug discontinuation.
• Hemolytic Anemia: A rare immune-mediated reaction where anti-penicillin antibodies lead to destruction of red blood cells.
• Neurotoxicity: Can occur with very high doses, especially in patients with renal impairment where the drug accumulates. Manifestations include myoclonus, hyperreflexia, seizures, and encephalopathy. This is due to Penicillin G acting as a GABA antagonist in the central nervous system.
• Jarisch-Herxheimer Reaction: Not a direct adverse effect of the drug, but an acute febrile reaction with headache, myalgia, and exacerbation of skin lesions that can occur within hours of initiating treatment for spirochetal infections like syphilis. It is caused by the release of inflammatory cytokines from lysed organisms.
• Electrolyte Imbalance: High-dose intravenous potassium penicillin G delivers a substantial potassium load (approximately 1.7 mEq of K⁺ per million units), which can cause hyperkalemia, particularly in patients with renal failure. Sodium penicillin G can contribute to sodium load and fluid retention.

There are no FDA-mandated black box warnings for Penicillin G, but the risk of severe hypersensitivity reactions, including anaphylaxis, is prominently highlighted in its prescribing information.

7. Drug Interactions

Penicillin G participates in several pharmacologically significant drug interactions, primarily mediated through competition for renal tubular secretion or additive toxicities.

Major Drug-Drug Interactions

• Probenecid: Probenecid competitively inhibits the organic anion transporter responsible for the active tubular secretion of Penicillin G. This inhibition decreases renal clearance, prolongs the elimination half-life, and increases serum concentrations of the antibiotic. This interaction can be used therapeutically to permit less frequent dosing or to achieve higher serum levels, such as in the treatment of neurosyphilis.
• Other Nephrotoxic Agents: Concurrent use with drugs like aminoglycosides, vancomycin, or non-steroidal anti-inflammatory drugs may increase the risk of acute interstitial nephritis or general nephrotoxicity.
• Methotrexate: Penicillins can reduce the renal clearance of methotrexate by competing for tubular secretion, potentially leading to methotrexate toxicity (myelosuppression, mucositis).
• Oral Anticoagulants (Warfarin): There are reports of penicillins potentiating the effects of warfarin, possibly by altering gut flora and reducing vitamin K production or through other mechanisms. Close monitoring of the International Normalized Ratio (INR) is advised.
• Bacteriostatic Antibiotics (e.g., Tetracyclines, Chloramphenicol): Theoretical antagonism may occur because penicillins require actively dividing bacteria to be effective, and bacteriostatic agents inhibit bacterial growth. This interaction is of variable clinical significance but is generally avoided in serious infections like meningitis or endocarditis.

Contraindications

The primary absolute contraindication to Penicillin G is a history of a previous severe hypersensitivity reaction (e.g., anaphylaxis, Stevens-Johnson syndrome) to any penicillin. Cross-reactivity with cephalosporins is estimated at 1-10%, primarily with first-generation agents, and caution is warranted in patients with a severe penicillin allergy. The procaine salt is contraindicated in patients with known hypersensitivity to procaine or other local anesthetics of the ester type.

8. Special Considerations

The use of Penicillin G requires careful adjustment in specific patient populations due to alterations in pharmacokinetics, potential toxicity, or unique risks.

Pregnancy and Lactation

Penicillin G is classified as FDA Pregnancy Category B. Extensive clinical experience indicates no consistent evidence of risk to the fetus. It is considered the antibiotic of choice for many infections in pregnant women, particularly syphilis, where treatment is essential to prevent congenital transmission. It is excreted in low concentrations in breast milk. While not generally contraindicated during breastfeeding, it may cause infant diarrhea, candidiasis, or allergic sensitization. The American Academy of Pediatrics considers it compatible with breastfeeding.

Pediatric Considerations

Neonates and infants have immature renal function, resulting in a significantly prolonged elimination half-life of Penicillin G. In a full-term neonate less than one week old, the half-life may be approximately 3 hours. Dosing must be adjusted accordingly, with longer intervals between doses. The repository formulations (procaine, benzathine) are used in children for indications like streptococcal pharyngitis and syphilis, with dosing based on body weight. The risk of procaine toxicity from the procaine formulation must be considered.

Geriatric Considerations

Age-related decline in renal function is common in elderly patients. Since Penicillin G is primarily renally eliminated, standard adult doses may lead to drug accumulation and an increased risk of neurotoxicity (seizures) and electrolyte disturbances. Estimation of creatinine clearance using a formula such as the Cockcroft-Gault equation is essential for determining appropriate dosing intervals. Volume of distribution may also be altered due to changes in body composition.

Renal Impairment

Dose adjustment is mandatory in renal impairment. As glomerular filtration rate (GFR) declines, the half-life of Penicillin G increases dramatically. In anuric patients, the half-life can extend to 6-10 hours. Dosing guidelines typically recommend extending the dosing interval rather than reducing the individual dose to ensure that peak concentrations remain bactericidal. In patients on intermittent hemodialysis, Penicillin G is significantly dialyzable, and a supplemental dose is usually required after each dialysis session.

Hepatic Impairment

No specific dose adjustment is required for hepatic impairment, as the liver plays a minimal role in the elimination of Penicillin G. However, caution is advised in severe hepatic disease due to potential alterations in fluid and electrolyte balance and coagulation status, which could be exacerbated by the sodium or potassium load from the drug.

9. Summary/Key Points

Penicillin G remains a cornerstone of antimicrobial therapy for specific, susceptible infections. Its pharmacology exemplifies the principles of targeted antibacterial action and the critical relationship between pharmacokinetics and dosing.

Clinical Pearls

• Penicillin G is a narrow-spectrum, bactericidal beta-lactam antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to penicillin-binding proteins (PBPs).
• It is destroyed by gastric acid and must be administered parenterally (IV, IM) for systemic effect. The choice of salt (potassium, procaine, benzathine) dictates the absorption profile and clinical application.
• Renal excretion via glomerular filtration and active tubular secretion is rapid, resulting in a very short half-life (30-60 min) in normal renal function, necessitating frequent or continuous dosing for serious infections.
• First-line indications include infections caused by susceptible streptococci, syphilis (all stages), clostridial infections, and meningococcal meningitis.
• Hypersensitivity reactions are the most common adverse effects, ranging from mild rash to life-threatening anaphylaxis. A thorough allergy history is imperative prior to administration.
• Serious toxicities include neurotoxicity (seizures) with high doses in renal impairment, interstitial nephritis, and electrolyte disturbances from the potassium or sodium salt load.
• Probenecid significantly increases Penicillin G levels by inhibiting its renal tubular secretion, an interaction that can be used therapeutically.
• Dose adjustment is essential in neonates and patients with renal impairment due to prolonged elimination. No adjustment is needed for hepatic impairment.

Mastery of the pharmacology of Penicillin G provides an essential foundation for understanding all beta-lactam antibiotics and for the rational, safe, and effective use of this historic yet enduring antimicrobial agent.

References

1. Gilbert DN, Chambers HF, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy. 53rd ed. Sperryville, VA: Antimicrobial Therapy Inc; 2023.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
5. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.